Pretty much done, page-5

Strong themes on this thread! My story; I bought late Nov 2016 a month after the admission to the ASX. My rationale was 2 fold, based on the product (which I like - still) and the sales base from the "8,700 unit take or pay" contract with Promosalute. I sold at 29 cents because I was sick of the falling price (well done me!). NTI told us that the Proposalute contract was renegotiated in August 2017; the timings were changed but not the volumes. I can't find another specific reference to this deal in any subsequent announcements. I suspect it is being "renegotiated" again; management is deciding not to enforce the deal (this on the basis that the longer term value of the relationship!?!?). Scammed? Dunno. Incompetence? Also dunno. There is a legitimate issue over sales performance given the distribution agreements they tell us they have.

What am I gonna do? There will be a small CR early next year to get them past FDA approval. I bet management is hoping the SP will go up in the lead up to US FDA approval and they will be able to get a big CR away after that for commercialisation. I believe in the product but am on the sidelines for a while yet.